Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, Inc., today announced the initiation of a Phase IB clinical study in chronic obstructive pulmonary disease (COPD) with their lead clinical candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule product emerging from the company’s iSPERSE™ technology, a novel inhaled dry powder delivery platform. The clinical trial will evaluate the safety, tolerability and the pharmacokinetic/pharmacodynamic profile as well as dose response of PUR0200 in moderate COPD patients. GOLD Stage 2/3 COPD patients will be enrolled in a five-way placebo controlled crossover study.
Help employers find you! Check out all the jobs and post your resume.
